This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Abbott (ABT) Stock Moves -0.3%: What You Should Know
by Zacks Equity Research
Abbott (ABT) concluded the recent trading session at $109.52, signifying a -0.3% move from its prior day's close.
Abbott (ABT) Stock Moves -0.2%: What You Should Know
by Zacks Equity Research
The latest trading day saw Abbott (ABT) settling at $109.85, representing a -0.2% change from its previous close.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Brokers Suggest Investing in Abbott (ABT): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Abbott (ABT) Laps the Stock Market: Here's Why
by Zacks Equity Research
In the closing of the recent trading day, Abbott (ABT) stood at $109.79, denoting a +0.51% change from the preceding trading day.
Watch These 5 Stocks That Recently Hiked Dividends
by Zacks Equity Research
Investors may keep a tab on stocks like FULT, SFBS, MOS, ABT and ANDE, which have lately hiked their dividend payments.
PETQ or ABT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PETQ vs. ABT: Which Stock Is the Better Value Option?
Here's Why Abbott (ABT) Gained But Lagged the Market Today
by Zacks Equity Research
Abbott (ABT) reachead $108.42 at the closing of the latest trading day, reflecting a +0.33% change compared to its last close.
Abbott (ABT) Rises Higher Than Market: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Abbott (ABT) stood at $108.06, denoting a +0.72% change from the preceding trading day.
Abbott (ABT) Gains From Global Expansion Amid Macro Woes
by Zacks Equity Research
Abbott's (ABT) EPD business continues to witness low double-digit growth. It has successfully positioned itself as one of the best-positioned large healthcare companies in emerging markets.
Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for NOBL
The Zacks Analyst Blog Highlights JPMorgan Chase, Abbott Laboratories, Qualcomm, Johnson & Johnson and BHP
by Zacks Equity Research
JPMorgan Chase, Abbott Laboratories, Qualcomm, Johnson & Johnson and BHP are included in this Analyst Blog.
Top Stock Reports for JPMorgan, Abbott, Qualcomm & Others
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT) and Qualcomm, Inc. (QCOM).
Abbott (ABT) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
Abbott (ABT) concluded the recent trading session at $106.68, signifying a +0.43% move from its prior day's close.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Abbott (ABT) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, Abbott (ABT) stood at $104.94, denoting a +0.57% change from the preceding trading day.
PETQ vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
PETQ vs. ABT: Which Stock Is the Better Value Option?
Abbott (ABT) Rises Higher Than Market: Key Facts
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $104.29, moving +0.64% from the previous trading session.
Wall Street Bulls Look Optimistic About Abbott (ABT): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) driven by expansion in the global market and raised guidance.
Abbott (ABT) Benefits From Innovation Amid FX Headwinds
by Zacks Equity Research
Abbott's (ABT) mAbxience collaboration is likely to help introduce cutting-edge medicines in the areas of oncology, women's health and respiratory diseases.
Top Analyst Reports for Novo Nordisk, Bank of America & Netflix
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Bank of America Corporation (BAC) and Netflix, Inc. (NFLX).
PETQ vs. ABT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PETQ vs. ABT: Which Stock Is the Better Value Option?